Posted by Michael Wonder on 15 Aug 2023
Venatorx Pharmaceuticals announces FDA acceptance and priority review of new drug application for cefepime-taniborbactam to treat complicated urinary tract infections, including pyelonephritis, in adults
15 August 2023 - PDUFA action date set for 22 February 2024.
Venatorx Pharmaceuticals today announced that the US FDA has accepted the company’s new drug application for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor antibiotic for the potential treatment of adult patients with complicated urinary tract infections, including pyelonephritis.
